Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
68
MREO Quote, Financials, Valuation and Earnings
Last price:
$2.31
Seasonality move
:
15.38%
Day range:
$2.22 - $2.33
52-week range:
$1.47 - $3.88
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
715.06x
P/B ratio:
7.81x
Volume:
2.1M
Avg. volume:
2.2M
1-year change:
-32.45%
Market cap:
$364.1M
Revenue:
--
EPS (TTM):
-$0.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group Plc
|
$5M | -$0.00 | -100% | -88.64% | $7.20 |
|
AUTL
Autolus Therapeutics Plc
|
$21.3M | -$0.23 | 84624.25% | -288.08% | $9.52 |
|
BCYC
Bicycle Therapeutics Plc
|
$8.2M | -$1.07 | 92.62% | -25.75% | $21.50 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group Plc
|
$2.29 | $7.20 | $364.1M | -- | $0.00 | 0% | 715.06x |
|
AUTL
Autolus Therapeutics Plc
|
$1.65 | $9.52 | $437.8M | -- | $0.00 | 0% | 8.54x |
|
BCYC
Bicycle Therapeutics Plc
|
$6.93 | $21.50 | $480.7M | -- | $0.00 | 0% | 16.94x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$3.22 | $17.94 | $2.7M | -- | $0.00 | 0% | 0.73x |
|
NCNA
NuCana Plc
|
$3.31 | $104.00 | $13.8M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MREO
Mereo BioPharma Group Plc
|
0.85% | 0.598 | 0.12% | 8.09x |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 3.892 | 74.96% | 4.83x |
|
BCYC
Bicycle Therapeutics Plc
|
1.04% | 2.129 | 1.21% | 9.36x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.246 | -- | 1.20x |
|
NCNA
NuCana Plc
|
0.52% | -0.585 | 0.95% | 4.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group Plc
|
-- | -$10.3M | -67.41% | -70.81% | -2099.86% | -$7.3M |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BCYC
Bicycle Therapeutics Plc
|
$9.9M | -$72.9M | -33.96% | -34.37% | -624.9% | -$71.3M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
Mereo BioPharma Group Plc vs. Competitors
-
Which has Higher Returns MREO or AUTL?
Autolus Therapeutics Plc has a net margin of -2923.31% compared to Mereo BioPharma Group Plc's net margin of -373.3%. Mereo BioPharma Group Plc's return on equity of -70.81% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group Plc14% -$0.04 $47M AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About MREO or AUTL?
Mereo BioPharma Group Plc has a consensus price target of $7.20, signalling upside risk potential of 214.48%. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.52 which suggests that it could grow by 450.42%. Given that Autolus Therapeutics Plc has higher upside potential than Mereo BioPharma Group Plc, analysts believe Autolus Therapeutics Plc is more attractive than Mereo BioPharma Group Plc.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group Plc6 0 0 AUTLAutolus Therapeutics Plc9 0 0 -
Is MREO or AUTL More Risky?
Mereo BioPharma Group Plc has a beta of 0.376, which suggesting that the stock is 62.425% less volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.013, suggesting its more volatile than the S&P 500 by 101.348%.
-
Which is a Better Dividend Stock MREO or AUTL?
Mereo BioPharma Group Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group Plc pays -- of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or AUTL?
Mereo BioPharma Group Plc quarterly revenues are --, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. Mereo BioPharma Group Plc's net income of -$7M is higher than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Mereo BioPharma Group Plc's price-to-earnings ratio is -- while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group Plc is 715.06x versus 8.54x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group Plc715.06x -- -- -$7M AUTLAutolus Therapeutics Plc8.54x -- $21.1M -$78.6M
-
Which has Higher Returns MREO or BCYC?
Bicycle Therapeutics Plc has a net margin of -2923.31% compared to Mereo BioPharma Group Plc's net margin of -503.67%. Mereo BioPharma Group Plc's return on equity of -70.81% beat Bicycle Therapeutics Plc's return on equity of -34.37%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group Plc14% -$0.04 $47M BCYCBicycle Therapeutics Plc85.04% -$0.85 $625M -
What do Analysts Say About MREO or BCYC?
Mereo BioPharma Group Plc has a consensus price target of $7.20, signalling upside risk potential of 214.48%. On the other hand Bicycle Therapeutics Plc has an analysts' consensus of $21.50 which suggests that it could grow by 199.03%. Given that Mereo BioPharma Group Plc has higher upside potential than Bicycle Therapeutics Plc, analysts believe Mereo BioPharma Group Plc is more attractive than Bicycle Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group Plc6 0 0 BCYCBicycle Therapeutics Plc6 4 0 -
Is MREO or BCYC More Risky?
Mereo BioPharma Group Plc has a beta of 0.376, which suggesting that the stock is 62.425% less volatile than S&P 500. In comparison Bicycle Therapeutics Plc has a beta of 1.475, suggesting its more volatile than the S&P 500 by 47.505%.
-
Which is a Better Dividend Stock MREO or BCYC?
Mereo BioPharma Group Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group Plc pays -- of its earnings as a dividend. Bicycle Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or BCYC?
Mereo BioPharma Group Plc quarterly revenues are --, which are smaller than Bicycle Therapeutics Plc quarterly revenues of $11.7M. Mereo BioPharma Group Plc's net income of -$7M is higher than Bicycle Therapeutics Plc's net income of -$58.7M. Notably, Mereo BioPharma Group Plc's price-to-earnings ratio is -- while Bicycle Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group Plc is 715.06x versus 16.94x for Bicycle Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group Plc715.06x -- -- -$7M BCYCBicycle Therapeutics Plc16.94x -- $11.7M -$58.7M
-
Which has Higher Returns MREO or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -2923.31% compared to Mereo BioPharma Group Plc's net margin of --. Mereo BioPharma Group Plc's return on equity of -70.81% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group Plc14% -$0.04 $47M BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About MREO or BDRX?
Mereo BioPharma Group Plc has a consensus price target of $7.20, signalling upside risk potential of 214.48%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 5256.97%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Mereo BioPharma Group Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Mereo BioPharma Group Plc.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group Plc6 0 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is MREO or BDRX More Risky?
Mereo BioPharma Group Plc has a beta of 0.376, which suggesting that the stock is 62.425% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.955, suggesting its less volatile than the S&P 500 by 4.507%.
-
Which is a Better Dividend Stock MREO or BDRX?
Mereo BioPharma Group Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group Plc pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or BDRX?
Mereo BioPharma Group Plc quarterly revenues are --, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Mereo BioPharma Group Plc's net income of -$7M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Mereo BioPharma Group Plc's price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group Plc is 715.06x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group Plc715.06x -- -- -$7M BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns MREO or NCNA?
NuCana Plc has a net margin of -2923.31% compared to Mereo BioPharma Group Plc's net margin of --. Mereo BioPharma Group Plc's return on equity of -70.81% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group Plc14% -$0.04 $47M NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About MREO or NCNA?
Mereo BioPharma Group Plc has a consensus price target of $7.20, signalling upside risk potential of 214.48%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 628298.79%. Given that NuCana Plc has higher upside potential than Mereo BioPharma Group Plc, analysts believe NuCana Plc is more attractive than Mereo BioPharma Group Plc.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group Plc6 0 0 NCNANuCana Plc0 1 0 -
Is MREO or NCNA More Risky?
Mereo BioPharma Group Plc has a beta of 0.376, which suggesting that the stock is 62.425% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.595, suggesting its more volatile than the S&P 500 by 59.472%.
-
Which is a Better Dividend Stock MREO or NCNA?
Mereo BioPharma Group Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group Plc pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or NCNA?
Mereo BioPharma Group Plc quarterly revenues are --, which are smaller than NuCana Plc quarterly revenues of --. Mereo BioPharma Group Plc's net income of -$7M is lower than NuCana Plc's net income of -$378.9K. Notably, Mereo BioPharma Group Plc's price-to-earnings ratio is -- while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group Plc is 715.06x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group Plc715.06x -- -- -$7M NCNANuCana Plc-- -- -- -$378.9K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 5.1% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
